4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InnoCare Pharma Limited (9969) operates in the Biotechnology industry and is headquartered in Beijing, China with about 1,388 employees. Its market capitalization is roughly HK$25 billion. In the fiscal year ended 2025-12-31, 9969 reported CNY 2.4B in revenue and CNY 642M in net income.
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
Interactive charts & full statements → Open the 9969 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 2.4B | CNY 1.0B | CNY 738M | CNY 625M | — |
| Gross Profit | CNY 2.2B | CNY 871M | CNY 610M | CNY 482M | — |
| Operating Income (EBIT) | CNY 496M | (CNY 526M) | (CNY 652M) | (CNY 731M) | — |
| Net Income | CNY 642M | (CNY 441M) | (CNY 631M) | (CNY 887M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 10.8B | CNY 9.4B | CNY 9.9B | CNY 10.3B | — |
| Total Liabilities | CNY 3.1B | CNY 2.7B | CNY 2.7B | CNY 2.7B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9969 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms